Early-phase studies point to efficacy of a nectin-4-targeting antibody-drug conjugate in cervical cancer
In advanced or metastatic disease, bulumtatug fuvedotin shows promising efficacy and manageable safety
The antibody–drug conjugate era in gynaecological cancers
Recent approvals are driving a shift toward biomarker-informed treatment strategies, rational combinations and personalised sequencing
New immunotherapy option emerges for low-risk gestational trophoblastic neoplasia
Adding first-line checkpoint inhibition to standard treatment shows promise to improve response in women
Next-generation PRAME-directed TCR T-cell therapy shows early activity in solid tumours
Tumour reduction was observed with IMA203CD8 across different PRAME-expressing cancers in a phase I trial
Dose-dense paclitaxel and novel combination maintenance therapies offer survival benefits in advanced ovarian cancer
Positive results are reported from the FZOCUS-1 and ICON8B studies
How therapeutically tractable is MUC1 as a tumour-associated antigen?
Early proof-of-concept is provided showing pan-tumour activity of a novel antibody–drug conjugate
Analysis identifies proteins VISTA and VEGF-A as prognostic of poor survival in recurrent ovarian cancer
High expression of specific immune-oncology proteins may have utility in identifying high-risk patients to inform future trial design
Survival benefits demonstrated with immunochemotherapy in platinum-resistant ovarian cancer
The ENGOT-ov65/KEYNOTE-B96 trial reported small but clinically relevant progression-free survival increments and significantly improved overall survival in platinum-resistant ovarian cancer
Machine learning approach identifies the enzyme MMP2 as a key target for drug repurposing in advanced cervical cancer
Additional treatment targets and potentially repurposable agents were identified based on chemoradiotherapy response, which could now be explored for further validation.
Challenging ageism in gynaecological cancers
Recent research indicates that older age remains a barrier to accessing optimal treatment, despite a growing number of patients over 70 with ovarian and endometrial tumours